Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract. Naronapride works through a differentiated dual ...

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, today announced the appointment of Joy Rowan, MS, MBA to the role of senior vice president, sales.

Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Concurrent with Dr. Gormley’s appointment to Aktis’ Board of Directors, current Board members Helen Kim and Oleg Nodelman plan to step down from Aktis’ Board of Directors, effective May 20, 2026.

The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual, ...

Dr. Sigurdur Y. Kristinsson, the Principal Investigator of iStopMM at the University of Iceland, will present to participants about IMF-led research in Iceland. Then, cyclists will take a tour of the ...

New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve’s Position to Execute Development and ...

CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging ...

SRXH provides update on performance through mid-April with an approximate 3.5% gain in hedging pool, driven by EMJX’s algorithm, and an approximate gain of 8% in its long treasury investment holdings ...

Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, is pleased to announce the appointment of Giacomo Braglia as a new ...